盟科药业业绩快报 2025年度亏损规模较上年同期收窄

Core Viewpoint - Mengke Pharmaceutical (688373.SH) reported a total operating revenue of 142 million yuan for the fiscal year 2025, representing a year-on-year growth of 8.83%, but incurred a net loss attributable to shareholders of 242 million yuan [1] Group 1: Financial Performance - The company achieved total operating revenue of 142 million yuan, marking an 8.83% increase compared to the previous year [1] - The net loss attributable to shareholders was 242 million yuan for the reporting period [1] - Despite remaining in a loss position, the scale of losses for operating profit, total profit, and net profit attributable to shareholders narrowed compared to the previous year [1] Group 2: Product and Market Strategy - During the reporting period, the company had only one product, Kantizolamine tablets, in the commercialization stage [1] - The company is actively exploring a market development model that combines self-operated teams with commercial distribution [1] - Due to being in a transitional phase, various collaborations have not yet fully launched, resulting in only a slight increase in main business revenue year-on-year [1] Group 3: Cost Management - The company implemented measures to enhance the precision management of sales, research and development, and administrative expenses, leading to a decrease in overall costs and expenses compared to the same period last year [1] - There was a reduction in idle funds used for purchasing trading financial assets, which resulted in a decline in fair value change gains [1]